• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vivek Ramaswamy Breathes New Life In Beaten Down BuzzFeed Stock: What's Going On?

    5/22/24 8:04:07 AM ET
    $BZFD
    $ROIV
    Telecommunications Equipment
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BZFD alert in real time by email

    On Wednesday, BuzzFeed Inc (NASDAQ:BZFD) shares gained after former republican Presidential candidate Vivek Ramaswamy took a 7.7% stake in BuzzFeed for about $3.2 million as per SEC filing.

    As per data from Benzinga Pro, BuzzFeed shares are trading on a strong session volume of 4.84 million compared to an average 100-day volume of 938.86k.

    Related: BuzzFeed Shares More Than Double Following $108.6M Complex Sale, Plans To Layoff 16% Staff.

    According to the SEC filing, Ramaswamy “will engage in a dialogue with (BuzzFeed’s) Board of Directors and/or management about numerous operational and strategic opportunities to maximize shareholder value, including a shift in the company’s strategy.”

    A multi-millionaire who dropped out of the U.S. presidential race in January this year, Ramaswamy founded the biotech firm Roivant Sciences Ltd (NASDAQ:ROIV).

     Once valued at $1.7 billion, Buzzfeed has experienced a steep decline in its stock value, prompting the company to divest its news operation and seek buyers for subsidiaries like Complex Networks.

    Recently, BuzzFeed entered into a multi-year license and strategic partnership with Independent Digital News and Media.

    The agreement merges well-known brands like The Independent, BuzzFeed U.K., Tasty U.K., Seasoned, and HuffPost U.K., consolidating them under The Independent’s leadership for operations in the U.K. and Ireland.

    Price Action: At the last check on Wednesday, BZFD shares were up 44.8% at $3.62 during the premarket session.

    Get the next $BZFD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BZFD
    $ROIV

    CompanyDatePrice TargetRatingAnalyst
    Roivant Sciences Ltd.
    $ROIV
    3/20/2026$35.00Outperform
    Bernstein
    BuzzFeed Inc.
    $BZFD
    11/21/2025$1.00Buy → Hold
    Craig Hallum
    Roivant Sciences Ltd.
    $ROIV
    9/2/2025$16.00Buy
    Citigroup
    Roivant Sciences Ltd.
    $ROIV
    7/10/2025$19.00Buy
    Goldman
    Roivant Sciences Ltd.
    $ROIV
    2/15/2024$17.00Outperform
    Wolfe Research
    Roivant Sciences Ltd.
    $ROIV
    1/5/2024$20.00Overweight
    Piper Sandler
    Roivant Sciences Ltd.
    $ROIV
    12/12/2023$14.00Buy
    Deutsche Bank
    Roivant Sciences Ltd.
    $ROIV
    10/17/2023$17.00Buy
    Guggenheim
    More analyst ratings

    $BZFD
    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Torti Frank

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/2/26 7:14:49 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Gline Matthew

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/1/26 7:20:32 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sukhatme Mayukh

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/1/26 7:19:14 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZFD
    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Roivant Sciences with a new price target

    Bernstein initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $35.00

    3/20/26 8:36:50 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BuzzFeed downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded BuzzFeed from Buy to Hold and set a new price target of $1.00

    11/21/25 7:50:53 AM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    Citigroup initiated coverage on Roivant Sciences with a new price target

    Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00

    9/2/25 8:40:38 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZFD
    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

    Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

    4/2/26 5:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

    Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

    4/2/26 5:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

    The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reductionAdditional analyses from VALOR, presented at the 2026 American Academy of Dermatology (AAD) Meeting, demonstrated meaningful improvements in itch and skin-related quality of life with brepocitinib 30 mgThe U.S. Fo

    3/28/26 3:00:00 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZFD
    $ROIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/18/25 7:28:11 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZFD
    $ROIV
    SEC Filings

    View All

    Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Roivant Sciences Ltd. (0001635088) (Filer)

    4/2/26 7:00:32 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

    SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    3/27/26 1:02:27 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Roivant Sciences Ltd.

    144 - Roivant Sciences Ltd. (0001635088) (Subject)

    3/26/26 4:14:58 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZFD
    $ROIV
    Financials

    Live finance-specific insights

    View All

    Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

    Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

    4/2/26 5:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BuzzFeed, Inc. Reports Q4 and Full Year 2025 Results

    BuzzFeed, Inc.'s ("BuzzFeed" or the "Company") (NASDAQ:BZFD) fourth quarter and full year (ended December 31, 2025) financial results were in line with its outlook shared in November. In 2025, BuzzFeed grew programmatic advertising by 7% year over year, expanded its studio business with three feature films, and advanced product innovation in key areas. "We believe there is a gap between the value of our individual assets and our market capitalization that suggests significant unrecognized upside," said Jonah Peretti, BuzzFeed Founder & CEO. "In 2026, our focus is demonstrating the value of our brands, Studio IP, and new AI apps to the market, and we're actively exploring strategic options

    3/12/26 4:15:00 PM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

    Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

    3/3/26 4:15:00 PM ET
    $ABUS
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZFD
    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BuzzFeed Inc.

    SC 13G/A - BuzzFeed, Inc. (0001828972) (Subject)

    11/14/24 9:00:49 AM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 4:58:58 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BZFD
    $ROIV
    Leadership Updates

    Live Leadership Updates

    View All

    Fathom Holdings Appoints Highly Experienced Technology Industry Expert Adam Rothstein to Board of Directors

    CARY, N.C., March 17, 2025 /PRNewswire/ -- Fathom Holdings, Inc. (NASDAQ:FTHM) ("Fathom"; or the "Company"), a national, technology-driven, end-to-end real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings for brokerages and agents, has appointed highly-experienced technology industry expert Adam Rothstein to its Board of Directors.  Mr. Rothstein will serve on the Company's Audit Committee, Nominating and Corporate Governance Committee, and its newly formed Strategy Committee. Mr. Rothstein, age 53, is a venture investor specializ

    3/17/25 4:05:00 PM ET
    $BZFD
    $FTHM
    $RSVR
    Telecommunications Equipment
    Consumer Discretionary
    Real Estate
    Finance

    Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

    NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

    3/26/24 6:22:00 PM ET
    $PGTI
    $ROIV
    $RUN
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

    BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

    11/10/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care